Patents by Inventor Reiko Namikawa

Reiko Namikawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Extended human hematopoiesis in a heterologous host
    Patent number: 6093872
    Abstract: A human hematopoietic system is provided in an immunocompromised mammalian host, where the hematopoietic system is functional for extended periods of time. Particularly, human fetal liver tissue and human fetal thymus is introduced into an appropriate site of a young immunocompromised mouse at a site supplied with a vascular system, whereby the fetal tissue results in novel formation of functional human bone marrow tissue.
    Type: Grant
    Filed: February 13, 1992
    Date of Patent: July 25, 2000
    Assignee: Systemix, Inc.
    Inventors: Hideto Kaneshima, Reiko Namikawa, Joseph McCrary McCune
  • Small animal metastasis model
    Patent number: 5643551
    Abstract: A method for initiating metastasis of human tumor cells under experimental conditions is provided. Immunocompromised non-human mammals having a viable, xenogeneic organ or tissue are used as a host for human tumor cells. The cells are introduced into the chimeric animal after the solid tissue is implanted and are then able to grow and metastasize as they would in situ. Therapeutic regimens may be evaluated in this system to determine efficacy against metastatic processes.
    Type: Grant
    Filed: October 26, 1994
    Date of Patent: July 1, 1997
    Assignee: Systemix, Inc.
    Inventors: Reiko Namikawa, Seishi Kyoizumi, Emilya Shtivelman, Joseph M. McCune
  • In vivo use of human bone marrow for investigation and production
    Patent number: 5633426
    Abstract: Chimeric immunocompromised hosts are provided, comprising human bone marrow of at least 4 weeks from the time of implantation. The bone marrow is found to assume the normal population of bone marrow except for erythrocytes. The bone marrow may be used to study the effect of various agents on the proliferation and differentiation of hematopoietic cells.
    Type: Grant
    Filed: February 10, 1994
    Date of Patent: May 27, 1997
    Assignee: Systemix, Inc.
    Inventors: Reiko Namikawa, Seishi Kyoizumi, Joseph M. McCune, Hideto Kaneshima
  • Extended human hematopoiesis in a heterologous host
    Patent number: 5625127
    Abstract: A human hematopoietic system is provided in an immunocompromised mammalian host, where the hematopoietic system is functional for extended periods of time. Particularly, human fetal liver tissue and human fetal thymus is introduced into an appropriate site of a young immunocompromised mouse at a site supplied with a vascular system, whereby the fetal tissue results in novel formation of functional human bone marrow tissue.
    Type: Grant
    Filed: May 4, 1995
    Date of Patent: April 29, 1997
    Assignee: SyStemix, Inc.
    Inventors: Hideto Kaneshima, Reiko Namikawa, Joseph M. McCune
  • Drug screening and treatment for HIV thymocyte depletion
    Patent number: 5612018
    Abstract: A method is provided for screening compounds for the ability to supress thymocyte depletion in thymuses of HIV-infected individuals, particularly enhancing the CD4.sup.+ -expressing population as compared to an untreated individual. Particularly, drugs are provided which allow for this result, cyclosporine A being exemplary.
    Type: Grant
    Filed: January 18, 1994
    Date of Patent: March 18, 1997
    Assignee: Systemix, Inc.
    Inventors: Mark L. Bonyhadi, Hideto Kaneshima, Joseph M. McCune, Reiko Namikawa, Lishan Su
  • Extended human hematopoiesis in a heterologous host
    Patent number: 5476997
    Abstract: A human hematopoietic system is provided in an immunocompromised mammalian host, where the hematopoietic system is functional for extended periods of time. Particularly, human fetal liver tissue and human fetal thymus is introduced into an appropriate site of a young immunocompromised mouse at a site supplied with a vascular system, whereby the fetal tissue results in novel formation of functional human bone marrow tissue.
    Type: Grant
    Filed: May 17, 1994
    Date of Patent: December 19, 1995
    Assignee: Systemix, Inc.
    Inventors: Hideto Kaneshima, Reiko Namikawa, Joseph M. McCune
  • Human lymphoid tissue in an immunocompromised host
    Patent number: 5411749
    Abstract: Human lymphoid tissue is introduced into an immunocompromised host to provide opportunities to investigate the effect of stimuli on the human immune system and obtain information and products from the stimulus. Particularly, methodology is provided for the production of human monoclonal antibodies by introducing lymphoid tissue into an immunocompromised host, stimulating the B-lymphocytes with an appropriate immunogen, harvesting the tissue and immortalizing and/or cloning the B-lymphocytes under conditions to obtain a stable supply of monoclonal antibodies.
    Type: Grant
    Filed: December 23, 1992
    Date of Patent: May 2, 1995
    Assignee: Systemix, Inc.
    Inventors: Susan K. Mayo, Reiko Namikawa, Hideto Kaneshima, Joseph M. McCune